In order to assess similarity of biotherapeutics, many regulatory agencies recommend a stepwise approach for demonstrating biosimilarity between a proposed biosimilar product and an innovative (reference) biological product. In particular, glycosylation critical quality attributes (gCQA) of biosimilar can significantly affect drug's quality, safety, and efficacy. Additionally, the glycosylation is highly heterogeneous because it is primarily influenced by external conditions such as host cell lines and culture conditions. Thus, assessment of gCQA are necessary for evaluation similarity of biosimilars now commg to market. Here, we discuss the state of the art in analytical technologies to assess biosimilarity regarding glycosylation from regulatory perspective.
저자
Myung Jin Oh [ 오명진 | Graduate School of Analytjcal Sdence and Technology, Chungnam Natjonal Unjyersjty, Dae.ieon, Korea ]
Hyun Joo An [ Graduate School of Analytjcal Sdence and Technology, Chungnam Natjonal Unjyersjty, Dae.ieon, Korea ]
본 학회는 화학, 생화학, 분자생물학, 미생물학, 식품공학, 의학, 약학, 유전공학 및 생물공학, 환경 및 기타 공업 등 전 분야의 탄수화물관련 이론과 기술을 연구 발전시키고 산학협동을 통해 이를 보급하여 국내 관련 산업의 발전 및 국민생활의 과학화에 기여하고자 하며, 이러한 목표와 비젼의 실현을 위해 회원들이 적극적인 참여와 활동을 전개하고자 한다.